Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print New approach to vaccine development provides potent, long-lasting immunity

New approach to vaccine development provides potent, long-lasting immunity

May 24, 2006

PITTSBURGH - The field of vaccine development is getting a boost from new research that has identified a promising vaccine delivery approach, which in animal studies produced long-term immune protection after just one immunization. University of Pittsburgh researchers, who report their findings in the journal Immunity, say the method has particular relevance for efforts aimed at preventing or controlling infectious diseases, such as HIV or influenza, or stopping the growth of cancer. In one set of studies using this delivery approach, a single immunization halted the progression of melanoma and significantly extended survival in a mouse model.

The approach makes use of an inactivated retrovirus, in this case, a modified lentiviral vector more commonly known for its ability to carry functional genes in certain types of gene therapy. Viral vectors in general have been of practical interest to vaccine researchers for their potential to deliver antigens from disease-causing microbes, or even cancer, in order to efficiently build immune defenses against such intruders. To date, the lentivirus has been overlooked in vaccine research. But, according to Pitt investigators, it has distinct advantages that make it a more promising approach for vaccine development than other viral vector or DNA-based vaccine approaches previously studied.




According to results of their studies, a single injection of the lentivector containing either a hepatitis B virus antigen, a melanoma tumor antigen, or a commonly studied model antigen induced a more potent and notably, long-lasting immune response compared to other immunization approaches. A population of specialized immune cells that reside within the top layers of the skin is due much of the credit, say the authors.

"Skin dendritic cells have long been considered the immune system's first line of defense," explains Louis D. Falo, Jr., M.D., Ph.D., professor and chairman of the department of dermatology, University of Pittsburgh School of Medicine, and the study's senior author. "But recent studies that looked at different viral vectors, including the most commonly studied vaccinia vector, have challenged this notion, suggesting that skin dendritic cells are not as important as the classical paradigm maintained. We find that with the lentivirus, it's precisely these skin dendritic cells that are responsible for the vector's more potent immune induction and sustained protection."

Because they exist on the surface of the skin, these cells are the first to recognize the presence of a foreign body, or antigen. Although no longer an active virus, the lentivector is cause enough for alarm, so the dendritic cells capture their prey and then journey to the lymph nodes with their captured invaders - the vector, and the antigens in the vector as stowaway passengers. In the lymph nodes, the dendritic cells present their bounty to the waiting T cells and program them to attack the foreign invader, subsequently generating the appropriate immune response.

As the other studies have found, and the Pitt team confirms, skin-derived dendritic cells play a lesser role when other vectors are used, merely serving as the transport system to the lymph nodes, where another population of dendritic cells takes over and presents the antigen to the T cells.

Importantly, the investigators found that despite being a foreign intruder itself, the lentivirus seemed to escape the notice of the immune system, even when introduced a second time, suggesting that it could be used repeatedly in the same patients.

"You might say the other viral vectors are a one-shot deal because the immune system recognizes the virus and responds against it the second time around," suggests Dr. Falo. "With lentivirus, it seems feasible to use the immunization approach multiple times in the same patient, such as for annual flu vaccination, or in preventing multiple different infections or cancers in the same patient or in the general population."

Taken together, the investigators say their findings have implications for the development of vaccines that involve cell-mediated immunity, including viral and bacterial infections, and cancer. In the next three-to-five years, they expect to initiate a clinical trial of the approach, most likely for patients with melanoma.

University of Pittsburgh Medical Center



Related Vaccine Development Current Events and Vaccine Development News Articles Vaccine Development Current Events and Vaccine Development News RSS Vaccine Development Current Events and Vaccine Development News RSS
Milestone biodefense publication by Elsevier journal Vaccine
Last week during the 'Vaccines for Biothreats and Emerging and Neglected Diseases Symposium' in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense.

UM School of Medicine researchers find extreme genetic variability in malaria parasite
Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world.

Outfoxing pox: Developing a new class of vaccine candidates
In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.

Frozen assets: NIAID researchers turn to unique resource for clues to norovirus evolution
A search through decades-old frozen infant stool samples has yielded rich dividends for scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

New 'adjuvant' could hold future of vaccine development
Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

Unique immunization method provides insights about protective anti-malaria immune response
In this week's New England Journal of Medicine, scientists in Singapore, The Netherlands and France report that they have developed a novel immunization method that will induce fast and effective protection in humans against the life-threatening malaria parasite, Plasmodium falciparum, which infects 350 to 500 million people world-wide and kills over one million people each year.

First genetically-engineered malaria vaccine to enter human trials
Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease.

Vi typhoid vaccine proves highly effective in young children
A new study has found that a currently available yet underused vaccine against typhoid fever is highly effective in young children and protects unvaccinated neighbors of vaccinees.

NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines.

Study offers insights into failed HIV-1 vaccine trial
Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection.
More Vaccine Development Current Events and Vaccine Development News Articles
Vaccines: From Concept to Clinic:  A Guide to the Development and Clinical Testing of Vaccines for Human Use

Vaccines: From Concept to Clinic: A Guide to the Development and Clinical Testing of Vaccines for Human Use
by Lawrence C. Paoletti (Editor), Pamela McInnes (Editor)

Designed with academic vaccine researchers in mind, this book presents a road map of how a vaccine develops from an idea in a researcher's imagination, to the lab bench, through preclinical evaluation, and into the clinic for safety and immunogenicity. The result of the editors' own efforts to glean practical information on the steps necessary to manufacture, bottle, and test their vaccines for clinical trials, this book provides answers to researcher questions such as:oHow do I identify antigens that would produce effective vaccines?oCan I produce a clinical lot of vaccine in my laboratory?oHow should a vaccine be bottled?oWhich FDA expectations must I meet?oWhat is an IND application and how do I file it?oWhich CFRs apply to production of a vaccine?

Molecular and Clinical Aspects of Bacterial Vaccine Development

Molecular and Clinical Aspects of Bacterial Vaccine Development
by Dlawer A. A. Ala'Aldeen (Editor), Carlos E. Hormaeche (Editor)

Preventable bacterial infections continue to be a major hazard to human health in an age which has experienced a proliferation in readily available vaccines for such diseases. Molecular and Clinical Aspects of Bacterial Vaccine Development examines the latest developments in bacterial vaccinology and the impact they have had on the control of bacterial infections by comprehensively reviewing old, current and future vaccines. Ten of the most globally prevalent bacterial pathogens are covered, providing an indepth analysis of novel strategies for vaccine design and of the state-of-the-art technology available in this field. This timely and authoritative review of vaccine development will be an essential source of information for scientists, clinicians and public health specialists, as well...

Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995

Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
by Louis Galambos (Author), Jane Eliot Sewell (Contributor)

Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.

Handbook of Cancer Vaccines (Cancer Drug Discovery and Development)

Handbook of Cancer Vaccines (Cancer Drug Discovery and Development)
by Michael A. Morse (Editor), Timothy M. Clay (Editor), H. Kim Lyerly (Editor)

An authoritative survey of the scientific background for therapeutic cancer vaccines, the challenges to their development, and their current uses in treating cancer. The authors examine the basic issues that effect all vaccines (such as immune adjuvants and prime-boost strategies), describe the methods for antigen discovery, and review the preclinical development phases for each major vaccine strategy. They also spell out the clinical results for cancer vaccines now beginning to be used in the treatment of many common cancers.

AIDS Vaccine Development: Challenges and Opportunities

AIDS Vaccine Development: Challenges and Opportunities
by Wayne C. Koff (Editor), Patricia Kahn (Editor), Ian D. Gust (Editor)



Vaccines for the 21st Century: A Tool for Decisionmaking

Vaccines for the 21st Century: A Tool for Decisionmaking
by Committee to Study Priorities for Vaccine Development (Author), Division of Health Promotion and Disease Prevention (Author), Institute of Medicine (Author), Kathleen R. Stratton (Editor), Jane S. Durch (Editor), Robert S. Lawrence (Editor)

(Institute of Medicine) A decision-maker's guide to setting priorities for vaccine development over the coming decade, offering an analytic framework and quantitative model for evaluation of disease conditions. Also provides a way to compare different forms of illness and set vaccine priorities without the risk of human suffering or casualty. DNLM: Vaccines.

Vaccine Research and Development (Vaccine Research and Developments)

Vaccine Research and Development (Vaccine Research and Developments)
by Koff (Author)

Serving as a complementary series to AIDS Research Reviews - edited by Drs. Wayne C. Koff, Flossie Wong-Staal, and Ronald C. Kennedy (Marcel Dekker, Inc.) - this new series reviews significant advances in immunization research and addresses scientific and public policy challenges for moving candidate vaccines from the laboratory to the population.;Exploring recent progress in immunology, vaccine development and improvement, and clinical trials, Vaccine Research and Developments: analyzes the capacity of lipophilic components to chemically modify peptide and protein antigens and augment their immunogenicity; discusses the potential of noninfectious packaging mutants to serve as prototype vaccines; provides a novel presentation system for peptide vaccines through the multiple antigen...

  AIDS vaccine development: challenges and opportunities.(Book review): An article from: Emerging Infectious Diseases
by Robert T. Chen (Author)

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on November 1, 2007. The length of the article is 566 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: AIDS vaccine development: challenges and opportunities.(Book review)
Author: Robert T. Chen
Publication: Emerging Infectious Diseases (Magazine/Journal)
Date: November 1, 2007
Publisher: Thomson Gale
Volume: 13 Issue: 11 Page: 1802(1)

Article Type: Book review

Distributed by Thomson...

The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine (Medical Ethics)

The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine (Medical Ethics)
by Christine Grady (Author)

National Institute of Nursing Research. Single-author review of the current state of HIV vaccine research from the perspective of the ethical aspects of human subject research.

  New approaches to vaccine development: Proceedings of a meeting
by Schwabe (Publisher)



© 2009 BrightSurf.com